Neumora Therapeutics (NMRA) Enterprise Value (2022 - 2026)

Neumora Therapeutics' Enterprise Value history runs 5 years deep, the most recent figure standing at -$147.1 million for Q1 2026.

• On a quarterly basis, Enterprise Value rose 41.02% year-over-year to -$147.1 million in Q1 2026; TTM through Mar 2026 was -$147.1 million, a 41.02% increase from a year earlier, with the FY2025 full-year figure at -$182.5 million, down 27.32% from the prior year.
• Enterprise Value grew to -$147.1 million in Q1 2026 per NMRA's latest filing, from -$182.5 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$124.5 million in Q2 2025 and bottomed at -$509.6 million in Q3 2023.
• The 5-year median for Enterprise Value is -$249.4 million (2025), against an average of -$274.3 million.
• Across the five-year window, Enterprise Value sank 101.8% in 2023 and surged 68.42% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$371.9 million in 2022, then dropped by 22.08% to -$454.0 million in 2023, then jumped by 68.42% to -$143.4 million in 2024, then decreased by 27.32% to -$182.5 million in 2025, then increased by 19.43% to -$147.1 million in 2026.
• Per Business Quant, the three latest NMRA Enterprise Value figures stand at -$147.1 million (Q1 2026), -$182.5 million (Q4 2025), and -$129.1 million (Q3 2025).